Search

Lorena R Lerner

from Newton, MA
Age ~52
Get Report
Also known as:
Lorena Rosemberg, Lorena Learner
Phone and address:
37 Westgate Rd, Newton, MA 02459
(617) 549-8979
Related to:
Susana Cohen Lerner
Connected to:
Aline Lerner, 41Anna M Lerner, 42Avi Lerner, 48Carolyn N Lerner, 59Clifford G Lerner, 72Devorah L Lerner, 72Dorene P Lerner, 70Faina Lerner, 43Hannah A Lerner, 36Harold D Lerner, 64

Lorena Lerner Phones & Addresses

  • 37 Westgate Rd, Newton Center, MA 02459 (617) 549-8979 (617) 332-0071
  • Newton, MA
  • 583 Vfw Pkwy, Chestnut Hill, MA 02467
  • 504 63Rd St, New York, NY 10021 (212) 369-1126

Publications

Us Patents

Anti-Ron Antibodies

View page
US Patent:
8603478, Dec 10, 2013
Filed:
Jul 6, 2011
Appl. No.:
13/177071
Inventors:
Kerry Whalen - Chelmsford MA, US
Steve Bottega - Cambridge MA, US
Andrea Boudrow - Peabody MA, US
Lyne Breault - Roslindale MA, US
Ting Chen - Acton MA, US
James Gifford - Somerville MA, US
May Han - Brookline MA, US
Jinwei Jiang - Chestnut Hill MA, US
Lorena Lerner - Newton Centre MA, US
Qing Liu - Acton MA, US
Kristan Meetze - Lexington MA, US
Sylvie Vincent - Somerville MA, US
Solly Weiler - Newton MA, US
Jeno Gyuris - Lincoln MA, US
Assignee:
AVEO Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 39/395
US Classification:
4241331, 4241391
Abstract:
Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Directed Complementation

View page
US Patent:
20060228302, Oct 12, 2006
Filed:
Apr 5, 2006
Appl. No.:
11/398171
Inventors:
Murray Robinson - Boston MA, US
Ronan O'Hagan - Brookline MA, US
Karuppiah Kannan - Cambridge MA, US
Ti Cai - Andover MA, US
Maria Chiu - Newton Centre MA, US
Lorena Lerner - Newton Centre MA, US
Jie Lin - West Roxbury MA, US
Yinghui Zhou - Belmont MA, US
International Classification:
A61K 49/00
C12N 5/06
C12N 15/09
US Classification:
424009200, 435455000, 435354000
Abstract:
A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

Anti-Ron Antibodies

View page
US Patent:
20140066603, Mar 6, 2014
Filed:
Nov 1, 2013
Appl. No.:
14/070070
Inventors:
Steve Bottega - Cambridge MA, US
Andrea Boudrow - Peabody MA, US
Lyne Breault - Roslindale MA, US
Ting Chen - Acton MA, US
James Gifford - Somerville MA, US
May Han - Brookline MA, US
Jinwei Jiang - Chestnut Hill MA, US
Lorena Lerner - Newton Centre MA, US
Qing Liu - Acton MA, US
Kristan Meetze - Lexington MA, US
Sylvie Vincent - Somerville MA, US
Solly Weiler - Newton MA, US
Jeno Gyuris - Lincoln MA, US
Assignee:
AVEO PHARMACEUTICALS, INC. - Cambridge MA
International Classification:
C07K 16/30
US Classification:
5303873, 5303897
Abstract:
Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Treatment Of Congestive Heart Failure And Other Cardiac Dysfunction Using A Gdf15 Modulator

View page
US Patent:
20220403015, Dec 22, 2022
Filed:
Feb 2, 2022
Appl. No.:
17/649732
Inventors:
- Boston MA, US
Lorena Lerner - Newton Centre MA, US
International Classification:
C07K 16/22
Abstract:
The invention provides methods and compositions of treating a subject having a cardiac-related disorder such as congestive or chronic heart failure (CHF), cardiac hypertrophy, cardiac hypotrophy, and other cardiac myopathies/dystrophies. The methods comprise administering an effective amount of a composition that modulates, for example, reduces or inhibits, GDF15 activity in the subject.

Dual Viruses And Dual Oncolytic Viruses And Methods Of Treatment

View page
US Patent:
20220380735, Dec 1, 2022
Filed:
Oct 9, 2020
Appl. No.:
17/767132
Inventors:
- Cambridge MA, US
Lorena LERNER - Cambridge MA, US
Christophe QUEVA - Cambridge MA, US
Craig A. STRATHDEE - Cambridge MA, US
Jennifer S. LEE - Cambridge MA, US
International Classification:
C12N 7/00
C12N 15/113
C12N 15/86
Abstract:
The present disclosure provides dual viruses capable of producing a primary virus and a secondary virus, and dual oncolytic viruses capable of producing a primary oncolytic virus and a secondary oncolytic virus.

Encapsulated Polynucleotides And Methods Of Use

View page
US Patent:
20210403950, Dec 30, 2021
Filed:
Nov 13, 2019
Appl. No.:
17/293153
Inventors:
- Cambridge MA, US
Edward KENNEDY - Cambridge MA, US
Lorena LERNER - Cambridge MA, US
International Classification:
C12N 15/86
A61K 9/51
A61K 35/768
A61P 35/00
Abstract:
The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.

Rgmc-Selective Inhibitors And Use Thereof

View page
US Patent:
20210380669, Dec 9, 2021
Filed:
Oct 23, 2019
Appl. No.:
17/285952
Inventors:
- Cambridge MA, US
Adriana Donovan - West Roxbury MA, US
Meghan McDonald - London, GB
Abhishek Datta - Boston MA, US
Allan Capili - Somerville MA, US
Kevin B. Dagbay - Brighton MA, US
Lorena Lerner - Newton MA, US
Leonard Ira Zon - Wellesley MA, US
Kevin Schutz - Lebanon NH, US
John Bukowski - Lebanon NH, US
Justin W. Jackson - Cambridge MA, US
International Classification:
C07K 16/18
A61P 7/06
Abstract:
Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.

Encapsulated Polynucleotides And Methods Of Use

View page
US Patent:
20200224220, Jul 16, 2020
Filed:
Jul 13, 2018
Appl. No.:
16/630990
Inventors:
- Cambridge MA, US
Edward M. KENNEDY - Cambridge MA, US
Lorena LERNER - Cambridge MA, US
International Classification:
C12N 15/88
C12N 15/11
C12N 15/63
C12N 7/00
Abstract:
The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.
Control profile
Lorena R Lerner from Newton, MA, age ~52 Get Report